AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04125810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic
Study NCT04125810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Administered IV
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Administered PO
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Administered PO
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered IV
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered IV
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV
Study NCT02539225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study NCT00111085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 1 mg/h
Description: Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Study NCT00111085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 5 mg/h
Description: Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Study NCT00111085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Description: Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Study NCT00111085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Study NCT00765271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study
Study NCT00765271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/ritonavir
Description: Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)
Study NCT00765271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)
Study NCT01735019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of remifentanil with TCI system
Description: A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
Study NCT01115959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valproic acid
Description: treatment of 1 month dosage of 400 mg BID
Study NCT01115959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo bid
Study NCT01115959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo bid
Study NCT02309034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jump exercise
Description: Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
Study NCT02309034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
Study NCT02309034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional guidance
Description: Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
Study NCT02309034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional guidance
Description: Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
Study NCT03473340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Capsule
Description: Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks
Study NCT03473340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks
Study NCT00096915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg
Study NCT00593697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab (9 weeks) + docetaxel
Description: Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 ->FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
Study NCT00593697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
Description: Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
Study NCT03182010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cesarean section incision closure using barbed sutures
Description: Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
Study NCT03182010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section incision closure using conventional sutures
Description: Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
Study NCT04756323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage
Study NCT04756323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage
Study NCT04756323 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02678572 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Melphalan/HDS
Description: Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
Study NCT03843021 — intervention group
Intervention type: OTHER
Intervention: VAD Infection Prevention Survey
Description: Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
Study NCT02531113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Study NCT00939978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEPO
Description: recombinant human erythropoietin(rhEPO)
Study NCT00939978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhEPO
Description: recombinant human erythropoietin(rhEPO)
Study NCT03680417 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-Rubella (MR) Vaccine
Description: Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
Study NCT03857958 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic retrograde cholangio-pancreatography
Description: In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
Study NCT03857958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic retrograde cholangio-pancreatography
Description: In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
Study NCT04164355 — intervention group
Intervention type: DRUG
Intervention: Tadalafil 20 MG
Description: To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
Study NCT03928496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
Study NCT03928496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
Study NCT01158157 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ACAM2000
Description: Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
Study NCT02298608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano Knife
Description: Percutaneous, CT guided, ablation of renal mass
Study NCT01826188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC 5mg/ml and CBS 50mg/ml
Description: olive oil containing THC and CBD
Study NCT01826188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: olive oil without cannabis
Study NCT00332163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion
Study NCT00332163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
Study NCT00332163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
Study NCT00332163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-emptive Skin Treatment
Description: Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
Study NCT00332163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reactive Skin Treatment
Description: Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
Study NCT02226146 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bertilimumab
Study NCT02085083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse
Description: The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email.
Study NCT02085083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention Arm
Description: Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
Study NCT04157491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib and anti PD-1 antibody
Description: Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
Study NCT01786525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: House Calls
Description: 60-minute home based educational intervention which will be administered by a health educator
Study NCT01786525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: House Calls
Description: 60-minute home based educational intervention which will be administered by a health educator
Study NCT03396185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
Study NCT02791997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
Study NCT02791997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological tests
Description: Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
Study NCT01786525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Patient-Centered Decision Support Intervention
Description: Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
Study NCT00791856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: 28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
Study NCT03997916 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Belun Ring
Description: All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
Study NCT03997916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSG
Description: All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
Study NCT02858882 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Screening of elite swimmers
Study NCT04562844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sociale cognition
Description: several social cognition test
Study NCT03281694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo skin patch and placebo oral solution
Study NCT03281694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine
Description: nicotine skin patch (7 mg/24 hrs) and placebo oral solution
Study NCT03281694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AVL-3288
Description: placebo skin patch and AVL-3288 oral solution (3 mg)
Study NCT03281694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine + AVL-3288
Description: nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
Study NCT03334396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT03151655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATTeRS Video
Description: Narrative-based video intervention and accompanying workbook
Study NCT00791856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone
Description: 14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
Study NCT03334396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT03151655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Didactic Video
Description: Education only video
Study NCT00648011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Description: 20/25mg, single dose fed
Study NCT00648011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Accuretic™ Tablets 20 mg/25 mg
Description: 20/25mg, single dose fed
Study NCT03334396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT03897647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Electric (GE) VScan
Description: This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
Study NCT03264820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Doppler
Description: - Laser measurements at the level of each finger at 47 °C and at ambient temperature
Study NCT03264820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser speckle
Description: - Laser measurements at the forearm
Study NCT03264820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain evaluation
Description: Visual scale assesment pain
Study NCT03264820 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate
Description: Measurement of blood pressure and heart rate
Study NCT01188265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Study NCT01188265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Study NCT01188265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg per day
Description: VPA plus dextromethorphan 60 mg per day
Study NCT01188265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: VPA plus placebo
Study NCT01188265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Description: VPA \& Dextromethorphan 30 mg per day
Study NCT03936049 — intervention group
Intervention type: DRUG
Intervention: Liraglutide
Description: Liraglutide dispensing claim is used as the exposure group
Study NCT03936049 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP-4 inhibitor dispensing claim is used as the reference group